BlossomHill Aligns With FDA on Phase 2 Dose, Launches Pivotal SOLARA-2 Trial
BLSM sits 35% above its 52-week low of $11.02.
Summary
BlossomHill disclosed FDA alignment on 50 mg twice daily as the recommended Phase 2 dose for BH-30643 and announced SOLARA-2, a single-arm pivotal Phase 2 trial in EGFR C797S-positive NSCLC designed with registrational intent, with first patient dosing expected in Q1 2027. The company also struck a companion diagnostic collaboration with Foundation Medicine for the C797S resistance mutation. Q3 2026 net loss widened to $24.0 million, or $1.29 per share, from $16.0 million a year earlier, driven by R&D expenses of $21.9 million versus $14.7 million. Cash stood at $224.9 million as of September 30, 2026, which management says funds operations into Q2 2028. This follows the September SOLARA Phase 1/2 update showing a 45% objective response rate and the August Fast Track designation. Next catalysts: first patient dosed in SOLARA-2 in Q1 2027 and the BH-501284 IND filing the same quarter.
At the time of this announcement, BLSM was trading at $14.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $471.7M. The 52-week trading range was $11.02 to $27.99. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.